Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 3Terminated 1No longer available 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Philadelphia Chromosome 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Infections 1Hepatitis C 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Sorafenib 29Nivolumab 15pembrolizumab 12Radiosurgery 9Bevacizumab 9atezolizumab 7regorafenib 5Radiotherapy 5Fluorouracil 5Doxorubicin 5lenvatinib 4Sunitinib 4Oxaliplatin 4Ipilimumab 4Gemcitabine 4Ethiodized Oil 4Erlotinib Hydrochloride 4Capecitabine 4TLC 388 3Radiofrequency Ablation 3Leucovorin 3Everolimus 3Cisplatin 3Blood Specimen Collection 3toripalimab 2phosphomannopentaose sulfate 2durvalumab 2cediranib 2avelumab 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Hepatocellular × peginterferon alfa-2a × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡